BY MARKETWIRE
-
Sonova CEO sees solid growth in cosmetic hearing aid market following new launches
” When a little item goes along that looks amazing and appears great, it expands,” states Sonova chief executive officer.
-
Zealand Pharma CEO predicts surge in user-paid weight loss treatments in coming years
” I really think that in a couple of years, you’ll see the user-paid section as the fastest-growing,” states Adam Steensberg, Chief Executive Officer of Zealand P…
-
Zealand Pharma boss expects 2026 to bring clarity on data potential
One of the most vital point in 2026 will certainly be brand-new information for Zealand’s crown gem, petrelintid, on which the biotech business partnered with Swiss Roche in …
-
Nordea sees strong US demand for Demant product
Demant’s Oticon Zeal hearing aid enjoys strong early demand in the US.
-
Rising Wegovy prescriptions don’t capture whole story, says analyst
Weekly development in Wegovy shots reveals tablet computers aren’t cannibalizing prescriptions.
-
ALK’s Neffy launch delayed in Canada, Danish market set for March
The launch of ALK’s adrenaline sinus spray, Neffy, is taking much longer than anticipated, yet the firm is established for a prepared launch in Denmark simply nearby.
-
Sonova CEO sees solid growth in cosmetic hearing aid market following new launches
”When a small product comes along that looks cool and sounds good, it grows,” says Sonova CEO.
-
ALK aims for double-digit growth in 2026
For the entire of 2025, ALK accomplished earnings development of 15% and overall earnings of DKK 6.3 bn (USD 993m).
-
Zealand Pharma nominates UCB veteran for its board of directors
Iris Loew-Friedrich belonged to UCB’s exec board from 2008 to 2024.
-
Genmab CEO points to Epkinly data as main event of the year
First-line therapy will possibly open a substantial market. Epkinly is currently accepted for DLBCL individuals that have actually gotten 2 or even more therapies.
